Sign In
Get Clay Free →

Suggestions

    Mark Sydenham

    Trial Manager at Institute of Cancer Research

    Professional Background

    Mark Sydenham is a dedicated professional in the field of scientific research with a strong emphasis on oncology, particularly in clinical trials. Currently serving as a Trial Manager at the esteemed Institute of Cancer Research (ICR), Mark has established a reputation for his meticulous approach to managing complex clinical studies. His role allows him to collaborate with some of the brightest minds in cancer research, contributing meaningfully to groundbreaking studies aimed at improving treatment outcomes for cancer patients.

    Education and Achievements

    Mark’s educational journey began at St Andrews School in Leatherhead, where he developed a keen interest in the sciences. He then pursued higher education at Portsmouth University, where he earned a Bachelor of Science with Honors (BSc Hons) in Biology. This foundational education equipped him with a robust understanding of biological sciences, which is crucial in his current role at ICR. With his academic background and practical experience, Mark is well-prepared to navigate the complexities of clinical trials and contribute to advancements in cancer treatment.

    Key Skills and Expertise

    With several years of experience in trial management, Mark is skilled in overseeing the planning, execution, and analysis of clinical trials, particularly in the oncology field. His expertise includes regulatory compliance, data management, patient recruitment strategies, and collaboration with multi-disciplinary teams. Mark's attention to detail ensures that all trial protocols are adhered to, thereby maintaining the ethical standards and scientific integrity of the research. This skill set not only enhances clinical study outcomes but also fosters an environment of innovation and progress in cancer research.

    Highlights

    Apr 28 · The Lancet
    Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial - The Lancet
    Aug 3 · Science Daily
    Targeted radiotherapy limits side effects of breast cancer treatment - Science Daily

    Related Questions

    What inspired Mark Sydenham to pursue a career in clinical trials management?
    How has Mark Sydenham’s education in biology influenced his work at the Institute of Cancer Research?
    What are some of the notable clinical trials Mark Sydenham has managed at the Institute of Cancer Research?
    In what ways does Mark Sydenham contribute to advancements in cancer treatment through his role as a trial manager?
    How does Mark Sydenham ensure regulatory compliance in the clinical trials he oversees?
    M
    Add to my network

    Location

    Sutton, England, United Kingdom